Targeted Protein Degradation Therapeutics
Arvinas is a clinical-stage biopharmaceutical company and pioneer of PROTAC protein degrader technology, harnessing the body's own ubiquitin-proteasome system to selectively degrade disease-causing proteins. Its pipeline spans oncology and neurology, with lead programs targeting the androgen receptor (ARV-110) and estrogen receptor (ARV-471) in partnership with Pfizer. The company's platform addresses historically undruggable targets, offering potential advantages over traditional inhibitor approaches.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2023
Sep 2018
Apr 2018
Oct 2015
Sep 2013
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
